These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11600361)

  • 21. Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin.
    MacGowan A; Rogers C; Holt HA; Wootton M; Bowker K
    J Antimicrob Chemother; 2000 Jul; 46(1):73-8. PubMed ID: 10882692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of recombinant murine granulocyte colony-stimulating factor with or without fluoroquinolone therapy on mixed-infection abscesses in mice.
    Stearne LE; Vonk AG; Kullberg BJ; Gyssens IC
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3668-75. PubMed ID: 16127038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae.
    Schentag JJ
    J Chemother; 2002 Feb; 14 Suppl 2():13-21. PubMed ID: 12003136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci.
    Rodriguez-Cerrato V; McCoig CC; Saavedra J; Barton T; Michelow IC; Hardy RD; Bowlware K; Iglehart J; Katz K; McCracken GH
    Antimicrob Agents Chemother; 2003 Jan; 47(1):211-5. PubMed ID: 12499193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination.
    Firsov AA; Vostrov SN; Lubenko IY; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2004 May; 23(5):451-6. PubMed ID: 15120722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and milk penetration of moxifloxacin after intramuscular administration to lactating goats.
    Cárceles CM; Villamayor L; Escudero E; Marín P; Fernández-Varón E
    Vet J; 2007 Mar; 173(2):452-5. PubMed ID: 16377219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-related selection of fluoroquinolone-resistant Escherichia coli.
    Olofsson SK; Marcusson LL; Strömbäck A; Hughes D; Cars O
    J Antimicrob Chemother; 2007 Oct; 60(4):795-801. PubMed ID: 17635875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults.
    Klossek JM; Siegert R; Nikolaidis P; Arvis P; Leberre MA;
    J Laryngol Otol; 2003 Jan; 117(1):43-51. PubMed ID: 12590855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Penetration of moxifloxacin into liver tissue.
    Justinger C; Schilling MK; Kees MG; Kauffels A; Hirschmann K; Kopp B; Kees F; Kollmar O
    Int J Antimicrob Agents; 2012 Jun; 39(6):505-9. PubMed ID: 22526014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamics of trovafloxacin in experimental pneumococcal meningitis: basis for dosage selection in children with meningitis.
    McCoig CC; Wubbel L; Jafri HS; Lutsar I; Bastero R; Olsen K; Shelton S; Friedland IR; McCracken GH
    J Antimicrob Chemother; 1999 May; 43(5):683-8. PubMed ID: 10382890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment.
    Barth J; Jäger D; Mundkowski R; Drewelow B; Welte T; Burkhardt O
    J Antimicrob Chemother; 2008 Sep; 62(3):575-8. PubMed ID: 18515790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporin-resistant Streptococcus pneumoniae.
    Ribes S; Taberner F; Domenech A; Cabellos C; Tubau F; Liñares J; Viladrich PF; Gudiol F
    J Antimicrob Chemother; 2006 May; 57(5):931-6. PubMed ID: 16507562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.
    Yoshimatsu T; Nuermberger E; Tyagi S; Chaisson R; Bishai W; Grosset J
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1875-9. PubMed ID: 12019103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gemifloxacin is effective in experimental pneumococcal meningitis.
    Smirnov A; Wellmer A; Gerber J; Maier K; Henne S; Nau R
    Antimicrob Agents Chemother; 2000 Mar; 44(3):767-70. PubMed ID: 10681354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
    Schafer J; Hovde LB; Simonson D; Rotschafer JC
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model.
    Kowalski RP; Romanowski EG; Mah FS; Yates KA; Gordon YJ
    Am J Ophthalmol; 2005 Sep; 140(3):497-504. PubMed ID: 16083841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem.
    Conte JE; Golden JA; Kelley MG; Zurlinden E
    Int J Antimicrob Agents; 2005 Dec; 26(6):449-56. PubMed ID: 16280244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lower lipoteichoic and teichoic acid CSF concentrations during treatment of pneumococcal meningitis with non-bacteriolytic antibiotics than with ceftriaxone.
    Stuertz K; Schmidt H; Trostdorf F; Eiffert H; Mäder M; Nau R
    Scand J Infect Dis; 1999; 31(4):367-70. PubMed ID: 10528875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.